Heart shield for breast cancer patients: new drug may prevent chemo side effect

NCT ID NCT07233499

Recruiting now Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

First seen Nov 18, 2025 · Last updated Jun 14, 2026 · Updated 25 times

Summary

This study tests if the heart drug nebivolol can protect the hearts of women with HER2-positive breast cancer who are receiving trastuzumab, a treatment that can weaken the heart. Researchers will measure heart function and quality of life in 56 participants over several months. The goal is to find a way to prevent heart damage without interfering with cancer treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Cancer Institute- Cairo University- Egypt
RECRUITING

Cairo, Egypt

Contact Phone: •••-•••-••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE BREAST CANCER